Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
166. S Lang M-KM, Cotte L. Impact of specific NRTI and PI exposure on the risk of myocardial<br />
infarction: A case-control study nested within FHDH ANRSC04. 16th Conference on<br />
Retroviruses and Op<strong>por</strong>tunistic Infections; Montreal, Canada. 2009.<br />
167. Arribas JR, Pulido F, D<strong>el</strong>gado R, Lorenzo A, Miralles P, Arranz A, et al. Lopinavir/ritonavir<br />
as single-drug therapy for ma<strong>int</strong>enance of HIV-1 viral suppression: 48-week results of a<br />
randomized, controlled, open-<strong>la</strong>b<strong>el</strong>, proof-of-concept pilot clinical trial (OK Study). J<br />
Acquir Immune Defic Syndr 2005;40(3):280-7.<br />
168. Escobar I, Pulido F, Perez E, Arribas JR, Garcia MP, Hernando A. [Pharmacoeconomic<br />
analysis of a ma<strong>int</strong>enance strategy with lopinavir/ritonavir monotherapy in HIV-infected<br />
patients]. Enferm Infecc Microbiol Clin 2006;24(8):490-4.<br />
169. Cameron DW, da Silva Barbara A, Arribas Jose R, Myers Robert A, B<strong>el</strong>los Nicho<strong>la</strong>os C,<br />
Gilmore N, et al. A 96 Week Comparison of Lopinavir/Ritonavir Combination Therapy<br />
Followed by Lopinavir/Ritonavir Monotherapy versus Efavirenz Combination Therapy. J<br />
Infect Dis 2008;198(2):234-40.<br />
170. Arribas J. JG, G. Fatkenheuer, M. N<strong>el</strong>son, N. Clumeck, F. Pulido et al. The MONET trial:<br />
darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients<br />
with HIV RNA < 50 copies/mL at bas<strong>el</strong>ine. 5th IAS Conference on HIV Pathogenesis,<br />
Treatment and Prevention; Cape Town. 2009.<br />
171. C Kat<strong>la</strong>ma VM, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM et al. Efficacy of<br />
darunavir/ritonavir as single-drug ma<strong>int</strong>enance therapy in patients with HIV-1 viral<br />
suppression: a randomized open-<strong>la</strong>b<strong>el</strong> non-inferiority trial, MONOI-ANRS 136. 5th IAS<br />
Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town.<br />
172. D<strong>el</strong>fraissy JF, F<strong>la</strong>ndre P, De<strong>la</strong>ugerre C, Ghosn J, Horban A, Girard PM, et al. Lopinavir/<br />
ritonavir monotherapy or plus zidovudine and <strong>la</strong>mivudine in antiretroviral-naive HIVinfected<br />
patients. AIDS 2008;22(3):385-93.<br />
173. Bierman WF, van Agtma<strong>el</strong> MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with<br />
ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009;23(3):279-91.<br />
174. Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, et al. Rational use of<br />
antiretroviral therapy in low-income and middle-income countries: optimizing regimen<br />
sequencing and switching. AIDS 2008;22(16):2053-67.<br />
175. Evaluation of three strategies of second-line antiretroviral treatment in Africa (Dakar –<br />
Bobo-Diou<strong>la</strong>sso – Yaoundé) (2LADY) [database on the Internet] 2009. Avai<strong>la</strong>ble from:<br />
http://clinicaltrials.gov/ct2/show/NCT00928187?term=2LADY&rank=1.<br />
176. Murphy R Sunpath H, Nijhawan A, McL<strong>el</strong><strong>la</strong>n M , Kuritzkes D. Lopinavir/ritonavir (LPV/r) + 2<br />
nucleosi<strong>de</strong> analogues as second-line ART in Protease-inhibitor naïve adults in South<br />
Africa: Outcomes and adverse effects. 15th Conference on Retroviruses and Op<strong>por</strong>tunistic<br />
Infections; 2008 February 3−6, 2008; Boston.<br />
145
Change language